Nine of Europe's largest pharmaceutical companies have issued an urgent appeal for the European Union to strengthen its support for biopharmaceutical innovation. The companies argue that the bloc does not adequately value the research and development work carried out by its drugmakers.
The call comes as the United States and China increasingly compete for leadership in biopharma innovation. The European companies are concerned that the region could lose its research heritage if policymakers do not act to improve the environment for drug discovery and development.
The appeal highlights a perceived gap between Europe's scientific capabilities and its policy priorities. The companies are asking the EU to take concrete steps to ensure that the region remains competitive on the global stage.